Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Executive Summary

Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.

You may also be interested in...



Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.

Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC

Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.

FDA Review Of Novartis' Entresto Shows Agency's Practical Side

Pivotal trial of Novartis' sacubitril/valsartan duo in heart failure did not conform to FDA's combination policy, but agency ultimately valued its mortality effect over statistical correctness.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel